 |
|
|
|
 |
|
|
| Article 1 to 4 out of 4 concerning Talecris BioTherapeutics
|
-
Talecris Continues Global Expansion into Europe
(12/04/2006)
Talecris Biotherapeutics GmbH established as a wholly-owned sales and service organization to serve more than 15 European countries
Talecris Biotherapeutics Inc. announced the establishment of Talecris Biotherapeutics GmbH, its European headquarters in Frankfurt, Germany. Europe represents the second expansion in 2006 for the North Carolina-based biotherapeutics manufacturer, ...
-
Bausch & Lomb Licenses rPlasmin from Talecris Biotherapeutics for Ophthalmic Use
(08/30/2006)
Bausch & Lomb and Talecris Biotherapeutics announced that Talecris has granted an exclusive worldwide license to Bausch & Lomb for recombinant Plasmin technology for use in ophthalmology. The companies will co-develop rPlasmin, a recombinant ...
-
Talecris Biotherapeutics' Manufacturing Processes Safeguard Against Avian Bird Flu
(11/14/2005)
Processes assure inactivation of enveloped viruses like H5N1, preventing potential transmission through Talecris' therapeutic plasma proteins
Continuing its commitment to providing reliable supplies of the safest possible products, Talecris Biotherapeutics has confirmed its plasma collection and manufacturing processes significantly remove or inactivate enveloped viruses, such as those ...
-
Talecris Biotherapeutics Strengthens its Executive Leadership Team
(10/31/2005)
Alberto Martinez, M.D. selected as new CEO, John Hanson becomes new CFO, and Mel Asbury named SVP, Human Resources
After a focused and methodical search, Talecris Biotherapeutics has completed its executive leadership team with the appointments of three experienced, highly regarded executives. Alberto Martinez, M.D., has assumed the position of President and ...
|
|
|
|
|
Top